1. Transcatheter heart valve interventions: where are we? Where are we going?
- Author
-
Cherif Sahyoun, Michael Haude, Helmut Baumgartner, Elena Andreassi Marinelli, Erika Saillant, Alec Vahanian, Martin Thoenes, Simon Redwood, Olaf Wendler, Jasmine Lennartz, Victoria Delgado, Marion Tschernich, Olivier Gerard, Evelyn Julia Zemke, Bernard Prendergast, Matthew Leafstedt, Karen Thomitzek, Markus Mueller, Bernard Iung, Lars Søndergaard, Thomas Modine, Jeroen J. Bax, Olaf Rörick, Francesco Maisano, Anders Himmelmann, Prendergast, Bd, Baumgartner, H, Delgado, V, Gerard, O, Haude, M, Himmelmann, A, Iung, B, Leafstedt, M, Lennartz, J, Maisano, F, Marinelli, Ea, Modine, T, Mueller, M, Redwood, Sr, Rorick, O, Sahyoun, C, Saillant, E, Sondergaard, L, Thoenes, M, Thomitzek, K, Tschernich, M, Vahanian, A, Wendler, O, Zemke, Ej, and Bax, Jj
- Subjects
Aortic valve ,medicine.medical_specialty ,Psychological intervention ,Heart Valve Diseases ,Regurgitation (circulation) ,030204 cardiovascular system & hematology ,Prosthesis Design ,Transcatheter Aortic Valve Replacement ,03 medical and health sciences ,0302 clinical medicine ,Bicuspid aortic valve ,Mitral valve ,Tricuspid valve ,medicine ,Humans ,Heart valve ,Intensive care medicine ,Heart Valve Prosthesis Implantation ,business.industry ,valvular heart disease ,Heart valve disease ,030229 sport sciences ,medicine.disease ,Heart Valves ,Progression-Free Survival ,medicine.anatomical_structure ,Heart Valve Prosthesis ,cardiovascular system ,Cardiology and Cardiovascular Medicine ,business - Abstract
Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups. As academic researchers, clinicians, industry, and patient stakeholders collaborate to research these broader indications for transcatheter valve interventions, it is essential to address (i) device durability and deliverability, (ii) specific anatomical needs (e.g. bicuspid aortic valves, aortic regurgitation, mitral and tricuspid valve disease), (iii) operator training, and (iv) the reinforced importance of the multidisciplinary Heart Team.
- Published
- 2018